Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Avantor, Inc. for allegedly misleading investors regarding the company's competitive position and financial performance during the class period from March 5, 2024, to October 28, 2025 [1][3]. Group 1: Allegations Against Avantor - The complaint alleges that Avantor and its executives violated federal securities laws by making false and misleading statements about the company's competitive positioning and failing to disclose the negative impacts of increased competition [3]. - Defendants misled investors by downplaying the effects of competition, claiming that Avantor's lab business was performing well and that the company had strong competitive advantages [4]. Group 2: Financial Performance and Stock Impact - On April 25, 2025, Avantor reported disappointing Q1 2025 results, cutting its guidance and announcing the resignation of CEO Michael Stubblefield, leading to a stock price decline of $2.57 (over 16.5%) from $15.50 to $12.93 [5]. - The company continued to report weak financial results, including a year-over-year decrease in net sales and a further reduction in guidance, resulting in a stock price drop of $2.08 (over 15%) from $13.44 to $11.36 on August 1, 2025 [6]. - On October 29, 2025, Avantor reported a net loss of $712 million and -5% organic revenue growth, leading to a significant stock price decline of $3.50 (over 23%) from $15.08 to $11.58 [7][8].

If you purchased or acquired securities in Stride between October 22, 2024 and October 28, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330Â (Ext. 1310). [You may also click here for additional information] NEW YORK, Nov. 14, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Stride, Inc. ("Stride" or the "Company") (NYSE: LRN) and reminds investors of ...

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of securities of Stride, Inc. for the period between October 22, 2024, and October 28, 2025, due to misleading statements and omissions regarding the company's products and services [1][5]. Group 1: Lawsuit Details - The class action lawsuit claims that Stride, Inc. made misleading statements about its products and services aimed at public and private schools, which included inflated enrollment numbers and non-compliance with statutory requirements [5]. - Investors are entitled to compensation without any out-of-pocket fees through a contingency fee arrangement if they purchased Stride, Inc. securities during the class period [2]. Group 2: Participation Information - Interested parties can join the class action by visiting the provided link or contacting the law firm directly for more information [3][6]. - A lead plaintiff must file a motion with the court by January 12, 2026, to represent other class members in the litigation [1][3]. Group 3: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has consistently ranked highly in securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Nov 12, 2025 3:07 PM Eastern Standard Time Stride Shareholder Alert By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors with Substantial Losses of Lead Plaintiff Deadline in Class Action Lawsuit Against Stride, Inc. - LRN Share NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Kahn Swick & Foti, LLC ("KSF†) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have untilJanuary 12, 2026 to file lead plaintiff ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Quanex Building Products Corporation due to alleged violations of federal securities laws, with a lead plaintiff deadline set for November 18, 2025 [2][5]. Group 1: Allegations Against Quanex - The complaint alleges that Quanex and its executives made false or misleading statements regarding the maintenance of tooling and equipment at its Tyman Mexico facility, which were significantly underinvested [5]. - It is claimed that the conditions of the tooling and equipment had degraded to near catastrophic levels, leading to significant costs and delays in expected benefits from the Tyman integration [5]. - The complaint also states that Quanex had previously identified these issues, contradicting positive statements made about the company's operations and prospects [5]. Group 2: Financial Impact - On September 4, 2025, Quanex reported a diluted EPS of ($6.04), a significant decline from $0.77 in the same period the previous year, and an adjusted EBITDA of $70.30 [7]. - The company disclosed ongoing operational issues related to the Tyman business in Mexico, which impacted results more than expected during the third quarter of 2025 [6]. - During an earnings call on September 5, 2025, CEO George Wilson noted that operational challenges negatively impacted EBITDA in the Hardware Solutions segment by almost $5 million in the third quarter alone [8]. Group 3: Stock Price Reaction - Following the announcement of the financial results and operational issues, Quanex's stock price fell by $2.73, or 13.1%, closing at $18.18 per share on September 5, 2025, with unusually heavy trading volume [8]. - The stock continued to decline, falling by $1.98, or 10.9%, to close at $16.20 per share on September 8, 2025, also on unusually heavy trading volume [8].

Core Viewpoint - A securities class action lawsuit has been filed against James Hardie Industries plc for allegedly misleading investors regarding the company's inventory and demand situation during the Class Period from May 20, 2025, to August 18, 2025 [1][2] Allegations of Misconduct - The complaint claims that James Hardie made false statements about strong demand and normal stock levels while knowing that its North America Fiber Cement distributors were destocking inventory as early as April and May 2025 [2] - As a result, the positive statements made by the company regarding its business operations and prospects were materially misleading and lacked a reasonable basis [2] Lead Plaintiff Process - Investors in James Hardie have until December 23, 2025, to seek appointment as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel [3] - The lead plaintiff will act on behalf of all class members and select counsel to represent the class, with the ability to share in any recovery not affected by the decision to serve as a lead plaintiff [3] Firm Background - Kessler Topaz Meltzer & Check, LLP is known for prosecuting class actions and has a reputation for recovering billions for victims of fraud and corporate misconduct [4]

Core Viewpoint - A class action lawsuit has been filed against Cytokinetics, Incorporated for allegedly making false and misleading statements regarding the expected FDA approval of aficamten, which could impact investor confidence and stock performance [1][2]. Summary by Sections Class Action Details - The class period for the lawsuit is from December 27, 2023, to May 6, 2025, with a deadline for participation set for November 17, 2025 [2]. - The complaint alleges that Cytokinetics misled investors by claiming that FDA approval for aficamten was expected in the second half of 2025, while failing to submit a necessary Risk Evaluation and Mitigation Strategy (REMS) [2]. Company Statements - Cytokinetics admitted to not submitting the REMS despite having multiple pre-NDA meetings with the FDA regarding risk mitigation, which indicates that the company's public statements were materially misleading [2]. Shareholder Participation - Shareholders who purchased shares during the class period are encouraged to contact the law firm for potential lead plaintiff appointments, although this is not required to participate in any recovery [2][3]. - Registered shareholders will receive updates through a portfolio monitoring software at no cost [3]. Law Firm Background - DJS Law Group specializes in securities class actions and corporate governance litigation, focusing on enhancing investor returns through advocacy [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against aTyr Pharma, Inc. due to allegations of misleading statements regarding the efficacy of its drug Efzofitimod, which led to significant financial losses for investors [2][5]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses in aTyr between January 16, 2025, and September 12, 2025, to discuss their legal rights [1]. - There is a deadline of December 8, 2025, for investors to seek the role of lead plaintiff in a federal securities class action against aTyr [2]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [4]. Group 2: Allegations Against aTyr - The complaint alleges that aTyr and its executives violated federal securities laws by making false and misleading statements about Efzofitimod, particularly regarding its ability to allow patients to taper off steroid usage [5]. - In the EFZO-FIT study, efzofitimod showed no significant change in mean daily oral corticosteroid (OCS) dose at week 48, with a reduction of 2.79 mg for the drug compared to 3.52 mg for placebo [6]. - Following the release of the study results, aTyr's stock plummeted by 83.25%, dropping from a market close of $6.03 on September 12 to $1.01 on September 15 [6].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased or sold Cepton, Inc. (NASDAQ: CPTN) common stock between July 29, 2024, and January 6, 2025, of the December 8, 2025, lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by December 8, 2025 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly [6]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company [4]. - The firm was ranked No. 1 by ISS Securities Class Action Services for the number of settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions for investors [4]. - In 2019, the firm secured over $438 million for investors, and its founding partner was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020 [4]. Group 3: Case Allegations - The lawsuit alleges that during the Class Period, defendants made materially false and misleading statements regarding Cepton's business and operations [5]. - Specific allegations include that Cepton received a credible third-party bid valuing the company at more than double the Koito Acquisition, which was not disclosed to shareholders [5]. - The Board of Directors allegedly failed to explore this offer meaningfully, depriving shareholders of the opportunity to consider the Koito Acquisition [5].

Core Points - Rosen Law Firm is reminding KBR, Inc. investors of the November 18, 2025 deadline to join a securities class action lawsuit related to the company's performance during the Class Period from May 6, 2025, to June 19, 2025 [1][2] Group 1: Class Action Details - Investors who purchased KBR securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by November 18, 2025 [3] - The lawsuit alleges that KBR made materially false and misleading statements regarding its partnership with HomeSafe and the ability to fulfill the Global Household Goods Contract, leading to investor damages when the truth was revealed [5] Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company [4] - The firm has been ranked No. 1 for securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions of dollars for investors [4] - In 2019, the firm secured over $438 million for investors, and its founding partner was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020 [4]